A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirtobrutinib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Sponsors Eli Lilly and Company

12 Dec 2023 Results (As of April 10, 2023, n=39) assessing safety and efficacy of oral pirtobrutinib as a monotherapy for patients with B-cell malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition
02 Nov 2023 According to an Eli Lilly and Company media release, results from this study will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego.
08 Dec 2022 Planned primary completion date changed from 30 Jun 2023 to 10 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com